对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者 应用奥贝胆酸和贝特类药物治疗的研究进展.

Poor response or intolerance to ursodeoxycholic acid may occur in the treatment of primary biliary cholangitis ( PBC), and after switch to obeticholic acid or fibrates alone or in combination, poor response or intolerance is also observed in some treatment regimens. Clinical studies on obeticholic acid and fibrates will gradually solve these issues, and obeticholic acid/ fibrates combined with ursodeoxycholic acid is safe and effective in PBC patients without advanced liver cirrhosis. [ABSTRACT FROM AUTHOR]